Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 116

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 116
---
 (in each case, the share numbers set forth below have been adjusted for the Reverse Stock Split):

| ● | a registration statement with                                                                                                               
 the SEC for purposes of registering the resale from time to time of up to 2,100,000 Shares of Common Stock, which consists of (i) 2,086,357 
 shares of Common Stock under the November 2024 Keystone Purchase Agreement and (ii) 13,643 shares of Common Stock under the February        
 2024 Keystone Purchase Agreement;                                                                                                           |

| ● | a registration statement with                                                                                                           
 the SEC for purposes of registering the resale from time to time of up to 266,191 Shares of Common Stock, which consists of (i) 250,000 
 Keystone Purchase Shares, (ii) 6,191 Keystone Commitment Shares, and (iii) 10,000 Arena Commitment Shares;                              |

| ● | a registration statement with                                                                                                                
 the SEC for purposes of registering (1) the resale from time to time of up to 357,737 shares of Common Stock, which consists of (i) 20,557   
 shares of Common Stock issued to certain selling securityholders for their portion of the merger consideration in connection with the        
 consummation of the Business Combination in exchange for shares of common stock of Legacy CERo; (ii) 200,800 shares of Common Stock issuable 
 upon the conversion of shares of our Series A Preferred Stock, purchased by certain investors pursuant to the First Securities Purchase      
 Agreement; (iii) 12,520 shares of Common Stock issuable upon the conversion of shares of our Series B Preferred Stock, purchased by certain  
 investors pursuant to the Second Securities Purchase Agreement; (iv) 31,712 shares of Common Stock initially issued to the Sponsor and       
 distributed to its members in a distribution-in-kind immediately prior to the Business Combination; (v) 10,000 shares of Common Stock        
 issued to the Sponsor, which are subject to forfeiture upon the vesting of the Tertiary Earnout Shares; (vi) 1,850 shares of Common Stock    
 issued to investors other than the Sponsor in a private placement concurrently with the Initial Public Offering; (vii) 16,495 shares         
 of our Common Stock issued to certain third-party vendors and service providers; (viii) 3,250 shares of Common Stock issuable upon the       
 exercise of warrants to purchase shares of our Common Stock that were converted from Legacy CERo warrants in connection with the